Li JJ, Chen L, Shao ZM. Response letter re: Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial. Ann Oncol 2025 Mar 30:S0923-7534(25)00127-9. doi: 10.1016/j.annonc.2025.
PMID: 40169111